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Abstract
Background: The Mediterranean fever (MEFV) gene codes for protein pyrin, one of the regulators of inflammasome
activity in innate immune cells. Mutations in this gene are considered the primary cause of Familial Mediterranean
fever, but are also found in other monogenic and multifactorial autoinflammatory diseases. The aim of the study
was to determine if healthy carriers of MEFV gene mutations and R202Q polymorphism have clinical manifestations
of inflammation and impaired oxidative stress parameters.
Methods: One hundred DNA samples from healthy volunteers (13.3 ± 8.87 years of age (mean ± SD); range 2–35)
were sequenced by ABI PRISM 310 automated sequencer (PE Applied Biosystems, Norwalk, USA). The Eurofever
questionnaire was used to collect retrospectively medical history data. Oxidative stress was determined by measuring
spectrophotometrically thiobarbituric acid reactive substances (TBARS) in plasma and erythrocytes, as well as advanced
oxidation protein products in plasma. Superoxide dismutase (SOD) activity was determined by McCord and Fridovich
method in plasma and erythrocytes, while the catalase erythrocyte activity was assessed using a catalase ELISA kit.
Results: We found heterozygous carriers of K695R/N mutations in 5 %, E148Q/N mutations in 6 %, R202Q homozygous
polymorphism in 10 % and heterozygous R202Q alterations in 45 % of healthy volunteers. The MEFV mutation carriers
and R202Q polymorphism homozygotes reported significantly more often recurrent febrile episodes (p = 0.009), diffuse
abdominal pain (p = 0.025), and malaise (p = 0.012) compared to non-carriers. Erythrocyte TBARS levels and plasma SOD
activity were higher in persons with MEFV mutations and R202Q/R202Q (p = 0.03 and p = 0.049, respectively).
Conclusions: Healthy individuals may bear E148Q and K695R MEFV gene mutations, as well as R202Q polymorphism in
homozygous state. The determined gene alterations contribute to a subtle oxidative stress and may be associated with
more frequent episodes of fever and unspecific inflammatory manifestations. An incomplete penetrance or variable
expressivity of R202Q in populations of different ethnicity could influence the expression of autoinflammatory diseases
phenotype.
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Background
The Mediterranean fever (MEFV) gene codes for the pro-
tein pyrin that is expressed in the cells of the innate im-
mune system, especially granulocytes, monocytes, synovial
fibroblasts and dendritic cells. Although the precise role
of pyrin has not yet been clearly determined, it is one of
the specific modulators of inflammasome, caspase-1 acti-
vation with interleukin-1β (IL-1β) production, activation
of nuclear factor-kB and leukocyte apoptosis [1–4].
Clinical consequences of altered inflammasome regula-
tion result from interleukin-1β effects and massive influx
of activated leukocytes into tissues. Activated neutrophils
and monocytes release proinflammatory cytokines, initiate
acute-phase inflammatory response and undergo oxidative
burst with an intense generation of reactive oxygen and
nitrogen species via the NADPH oxidase complex and
myeloperoxidase system [1–6].
The MEFV gene mutations are considered the pri-
mary cause of familial Mediterranean fever (FMF), the
most common periodic fever syndrome and the proto-
type of monogenic autoinflammatory disease (AID).
However, MEFV gene mutations are also frequently found
in other AIDs, including Behcet’s disease, Henoch-
Schönlein purpura, polyarteritis nodosa, ulcerative colitis,
multiple sclerosis, etc. The knowladge about its role in the
pathogenesis of these diseases is still obscure, but it is
hypothesized that MEFV mutations could predispose to
proinflammatory states [7–11].
Familial Mediterranean fever predominantly affects the
populations of eastern Mediterranean origin, such as
Turks, Jews, Arabs and Armenians. There is no official
registry of FMF prevalence in Serbia, and its clinical
diagnosis is very rare. The most frequent clinical mani-
festations of FMF are self-limited recurrent attacks of
high fever (>38 °C) and sterile serositis (mostly periton-
itis), synovitis and erysipeloid rash [1–3]. In the attack
period, there are high levels of acute-phase reactants,
leukocytosis and increased oxidative stress, evidenced by
defective antioxidant defenses and enhanced oxidation
products. The parameters usually return to normal in
the remission period. However, in some patients, sub-
clinical inflammation and oxidative stress are reported
during the disease-free period as well [12–15].
In a large percentage of FMF patients, these five
MEFV mutations are most frequently found: M680I,
M694V, M694I and V726A in exon 10, and E148Q in
exon 2. M694V homozygotes have a severe form of the
disease, while mutations, such as E148Q and V726A,
have a reduced penetrance and rarely cause any symp-
toms [2, 4, 16, 17].
The precise influence of R202Q alteration, in exon 2
of the MEFV gene, on inflammasome activity has been
analysed additionaly. A high frequency of R202Q hetero-
zygosity is detected in various populations and does not
seem to cause any autoinflammatory effect in its car-
riers. Since this high carrier rate could not be explained
by inbreeding or genetic drift, it is proposed to repre-
sent a selective advantage, a type of balancing selection,
possibly toward increased innate immune response to a
yet unidentified pathogen [3, [18–21]. In contrast, the
frequency of R202Q homozygosity is very low and has
been found to be associated with autoinflammatory
manifestations in FMF patients that do not have any
MEFV mutation or when R202Q is in compound het-
erozygous state with a mutation. This shows that des-
pite its low frequency, the R202Q homozygosity has a
high penetrance rate and suggests a potent dosage-
dependent pro-inflammatory effect [15, 21–23].
The aim of the study was to determine if healthy car-
riers of MEFV gene mutations and R202Q polymorphism
have clinical manifestations of inflammation and impaired
oxidative stress parameters.
Methods
The study was conducted in compliance with the
Declaration of Helsinki and Good Clinical Practice (GCP)
Guidelines. The relevant study documents were approved
by an independent Ethics Committee and the informed
consent forms were obtained from the participants.
This cross-sectional study was performed as an
addition to the recently published study by Debeljak M.
et al. [24] intended to evaluate the distribution of MEFV
gene mutations in healthy populations of South-East
Europe. One hundered healthy subjects (age > 2 years)
or their parents have signed informed consent for blood
samples to be collected for genetics and oxidative stress
parameters analysis, as well as medical history data. The
Eurofever project questionnaire [25, 26] was used to
collect retrospectivelly the data about occurrence of in-
flammatory clinical manifestations during their life. The
questionnaire is designed to recognize autoinflammatory
syndromes and to collect information about clinical pre-
sentations in patients with a genetically confirmed diag-
nosis of AID or suspected cases on the basis of positivity
of diagnostic criteria. A part of the questionnaire about
clinical manifestations describes the characteristics of
disease episodes for a recurrent disease course, with de-
tailed analysis of fevers (frequency, duration, triggers,
etc.), muco-cutaneous manifestations, musculoskeletal
system, lymphoid organs and other organ systems, consti-
tutional symptoms (fatigue, malaise, weight loss, insomnia,
etc.), surgical procedures, family history, laboratory find-
ings (routine and specific blood examinations), imaging
and drug therapy. Recurrent fever was defined as 3 or
more episodes of fever (≥38.0 °C) in a 6 months interval,
that lasted for a few days without any identified cause after
thorough examination, followed by a fever-free interval
(with a sense of well-being) of at least 2 weeks. Clinical
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manifestations were compared between the persons with
determined MEFV mutations and R202Q polymorphism
and the control group that comprised all the persons
withoutMEFV mutations.
Healthy volunteers can be considered as representative
of Serbian population since questionnaire and blood
samples were obtained when subjects were performing
routine blood tests for health check up. Inclusion criteria
were absence of acute and chronic illnesses, fever free
period of at least 2 weeks prior to the blood samples col-
lection, and a signed informed consent. Blood samples
with EDTA were collected at the Department of Pediatric
Rheumatology, Clinical Center in Nis, Serbia. 200 μl of
the whole blood was used for DNA isolation by DNeasy
Blood & Tissue Kit (QIAGEN Inc., Valencia, CA, USA).
The DNA samples were tested for the presence of MEFV
gene mutations within the multinational Eurofever Project
(EAHC, Project No2007332) [24–26]. The MEFV gene
exons 2 and 10 were amplified individualy by PCR. The
exon 2 (360 bp) was amplified using the forward 5′-AAA
ACGGCACAGATGATTCCG-3′ and reverse 5′-AAGGG
CCTGCACTCCTTC-3′ primers, and exon 10 (400 bp)
by the following primers: forward 5′-AGCAGGAAGAGA
GATGCAGTG-3′ and reverse 5′-TTGGAGACAAGACA
GCATGG-3′. The exon 10 amplicons were primarily
screened using Denaturing high performance liquid chro-
matography (dHPLC), for separation of those with normal
nucleotide sequences (WAVE®Systems 4500 Series, Trans-
genomic, Inc., Omaha: NE, USA). Thereafter, sequencing
was carried out using the Big Dye Terminator cycle se-
quencing kit and ABI PRISM 310 automated sequencer
(PE Applied Biosystems, Norwalk, USA). The exon 2
amplicons were directly sequenced using the same
method. The sequencing was performed at the Center
for Medical Genetics, University Children’s Hospital
Ljubljana, Slovenia. Obtained nucleotide sequences
were compared with MEFV gene sequences at the
[GenBank:NM_000243.2].
Complete blood count parameters were assessed using
COULTER® AcT Diff Analyzer (Beckman Coulter Corpor-
ation, Hialeah, FL, USA). For C-reactive protein (CRP) and
albumins concentration measurement we used fully
automated Erba Mannheim XL600 analyzer (ERBA
Diagnostics Mannheim Gmbh, Baden-Wurttemberg,
Germany). Erythrocyte sedimentation rate (ESR) was
assessed using the Westergren ESR method [27].
Lipid peroxidation was evaluated measuring thiobarbi-
turic acid reactive substances (TBARS) in plasma and
washed erythrocytes. TBARS in erythrocytes were
assessed spectrophotometrically using the method by
Jain et al. [28]. Trichloroacetic acid and tertiary butyl al-
cohol were added to erythrocytes in phosphate buffer
(pH-7.4) forming the chromogen. The absorption was
measured at 532 nm wavelength. TBARS concentration
was expressed as nmol/g of hemoglobin. TBARS con-
centration in plasma was determined spectrophotomet-
rically using the method by Andreeva et al. [29]. This
method is based on the reaction of malondialdehyde
(MDA) with thiobarbituric acid, at a high temperature
and low pH. Measurement of MDA-TBA2 chromogen
was than assessed at 532 nm wavelength.
Protein oxidation was measured spectrophotometric-
ally by determination of advanced oxidation protein
products (AOPP) in plasma, according to chloramine T
solution, which in the presence of potassium iodide have
absorbance at 340 nm [30].
Total superoxide dismutase (SOD) activity was mea-
sured in plasma and erythrocytes. The activities of both
SODs were determined by measuring the inhibition of
pyrogallol autoxidation [31]. This is a “negative” type of
reaction, as we measure the decrease of nitroblue tetra-
zolium oxidation at the expense of pyrogallol autoxida-
tion under alkaline conditions. One unit of SOD was
defined as the amount of enzyme that causes 50 % inhib-
ition of the pyrogallol autooxidation rate at 420 nm.
The catalase activity was determined in erythrocyte ly-
sates using a catalase ELISA kit (Enzo Life Sciences, Inc.,
Farmingdale, NY 11735, USA), according to the manu-
facturer’s instructions.
The results were expressed as means ± standard devia-
tions (SD) or medians ± interquartile range (IQR), as
required. Statistical analysis was conducted using Chi-
squared test for association (with Phi and Cramer’s V
test for the strength of association (Phi)), with statistical
significance at p < 0.05, and Fisher’s exact test when ne-
cessary. The Hardy-Weinberg principle was applied to
test for R202Q polymorphism. Conditional logistic re-
gression analysis for matched data was used to estimate
an interaction between genotype and clinical manifesta-
tions (outcome). Statistical analysis of oxidative stress
parameters was conducted using the Mann-Whitney U-
test. For correlation between the parameters we used
Spearman’s rank order correlation. Statistical analyses
were performed using SPSS 17.0 (SPSS, Chicago, IL,
USA) statistical program.
Results
Out of 100 healthy volonteeers enrolled, 47 were males and
53 females, with average age of 13.3 ± 8.87 years (mean ±
SD) (range 2–35). All study subjests were Caucasians of the
Serbian ethnicity, without family history of FMF or other
autoinflammatory disease and no consanguinity. No demo-
graphic differences were determined between persons with
differentMEFV genotype.
The DNA samples sequencing has found that 11 %
(n = 11) of subjects have MEFV gene mutations. No
homozygous mutation for MEFV gene was determined.
We have only found heterozygous MEFV gene mutation
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K695R/N (c.2084A >G) in exon 10 in 5 % (n = 5) of sub-
jects, and E148Q/N (c.442G > C) mutation in exon 2 in
6 % (n = 6) of subjects. These subjects comprised the
group we named “MEFV mutation carriers”.
The R202Q (c.605G > A) homozygous polymorphism
was found in 10 % (n = 10) of subjects, and we named
this group “R202Q homozygotes”. Only one subject had
heterozygous K695R/N mutation in combination with
R202Q homozygous state why we used his data for ana-
lysis in two groups (“MEFV mutation carriers” and
“R202Q homozygotes”). Data for the groups MEFV muta-
tion carriers and R202Q homozygotes were pulled to-
gether in larger group for more precise statistical analysis,
and we named this group “MEFV/R202Qhomo”.
Heterozygous R202Q polymorphism was fond in 45 %
(n = 45) of subjects, and they together with subjects with
no MEFV mutations nor R202Q polymorphism (N/N)
made the group named “control group” (n = 80) (N/N
plus R202Q/N) (average age of 15.3 ± 11.6 years). No
demographic differences were determined between sub-
jects in different groups.
The allele and genotype frequencies for R202Q poly-
morphism were in Hardy-Weinberg equilibrium. However,
the expected frequency of R202Q recessive phenotype (aa)
was quite low: 10.6 % (f(a) = 0.325).
Erythrocyte TBARS levels were higher in MEFV/
R202Qhomo group compared to the control group (p =
0.03, U = 84) (Fig. 1a). There was no difference in TBARS
concentrations in plasma (p = 0.946, U = 161), nor AOPP
levels (p = 0.322, U = 121), between the groups. There was
positive corelation between AOPP and erythrocyte TBARS
levels, but not statistically significant (rs = 0.643, p =
0.086). Plasma SOD levels were higher in MEFV/
R202Qhomo group than in the control group (p = 0.049,
U = 58.5) (Fig. 1b). Although the activities of erythrocyte
SOD and catalase were lower in MEFV/R202Qhomo
group, the difference was not statistically significant (for
both groups p = 0.439). The R202Q homozygotes had sig-
nificantly higher values of SOD plasma levels compared to
the control group (p = 0.001) (Table 1). All the examined
oxidative stress parameters did not show any important
differences among subjects who were heterozygous for
R202Q polymorphism and those without R202Q (N/N).
None of the subjects met clinical diagnostic criteria for
FMF or other autoinflammatory diseases. In order to
evaluate clinical manifestations in our subjects according
to the MEFV genotype, we compared clinical manifesta-
tions frequency between defined groups (Table 2). Data
was missing for 4 subjects in control group (N/N plus
R202Q/N), for different manifestations and their data
were excluded.
The subjects in MEFV/R202Qhomo group reported
significantly more often: recurrent febrile episodes of un-
known cause (p = 0.002, Phi = 0.319), diffuse abdominal
pain (p = 0.007, Phi = 0.277), peritonitis (p = 0.004, Phi =
0.321), and malaise/fatigue (p = 0.002, Phi = 0.349) com-
pared to control group (Fig. 2). The results revealed a
medium strong correlation between the occurrence of
recurrent fever and determined heterozygous MEFV
mutations and R202Q homozygosity. Average duration
of fever episodes were 3.64 ± 1.26 days, and they re-
occurred after 3.1 ± 1.2 months on the average.
Fig. 1 The significant difference of oxidative stress parameters in study subjects according to MEFV genotype group. a The TBARS concentrations
in erythrocytes (median ± IQR) according to the MEFV genotype. *p = 0.03, compared to others. b Total SOD activity in plasma (mean ± SD) according
to the MEFV genotype. *p = 0.001 and **p = 0.049, compared to others. MEFV/R202Qhomo - MEFV mutation carrier plus R202Q homozygotes group,
Control group - N/N and R202Q/N
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The subjects in MEFV mutation carriers group experi-
enced more often: recurrent febrile episodes of unknown
cause (p = 0.048, Phi = 0.213), diffuse abdominal pain
(p = 0.023, Phi = 0.256), peritonitis (p = 0.01, Phi = 0.326),
and malaise/fatigue (p = 0.006, Phi = 0.336), compared to
control group (n = 76). Subjects in R202Q homozygotes
group, compared to control group, had significantly higher
rates of recurrent fever (p = 0.022, Phi = 0.252), diffuse
abdominal pain (p = 0.047, Phi = 0.224), and lymphaden-
opathy (p = 0.049, Phi = 0.216).
According to the conditional logistic regression ana-
lysis, no mutation nor R202Q alteration could signifi-
cantly predict the development of most common clinical
manifestations in our study group.
Complete blood count parameters and basic biochem-
ical analyses (albumins, hemoglobin, CRP and ESR) were
not different between the groups. There was a positive
correlation between erythrocyte TBARS and leukocyte
count (rs = 0.838, p = 0.009), as well as between plasma
SOD levels and ESR (rs = 0.798, p = 0.031) in MEFV/
R202Qhomo group.
Discussion
The observed MEFV heterozygote mutation carrier rate
of 11 % is relatively high for the Serbian healthy popula-
tion. The clinical diagnosis of FMF, by applying Tel
Hashomer criteria, is very rare in Serbia. It is possible
that absence of FMF cases in Serbia is maybe due to the
lack of the most commonly found mutations (M694V,
V726A, M680I and M694I) and genotypes that are
found in other populations in Mediterranean area. The
mutations determined in our study were predominantly
heterozygous E148Q and K695R. The E148Q mutation
is frequently found in different populations and is usualy
associated with milder clinical features with reduced
penetrance. It is suggested to predispose to an inflam-
matory phenotype when in combination with other pro-
inflammatory factors [32, 33]. In contrast to E148Q,
K695R is considered a rare MEFV gene mutation. Gen-
erally, K695R has been found both as the sole mutation
in FMF patients and in asymptomatic individuals. Be-
cause of its weak phenotypic presentation it has been
supposed to predispose to subtle inflammatory changes
[17, 20, 33–35]. We did not determine M694V mutation
in our subjects and thus cannot say that there is linkage
disequilibrium with the R202Q variant. The p.Ser52Asn
of MVK and p.Gln703Lys of NLRP3 are not been ana-
lyzed and it would be interesting for further studies to
investigate association of these changes [36].
It is interesting that in different persons the same
MEFV mutation can be asymptomatic, it may present
with inflammatory symptoms, or even be considered
Table 1 Oxidative stress parameters according to the subjects genotype groups
Oxidative stress parameters MEFV mutation carriers (n = 11) R202Q homozygotes (n = 10) MEFV/R202Qhomo (n = 20) Control (n = 80)
TBARS in plasma (μmol/L) 2.36 ± 0.15 2.21 ± 0.12 2.327 ± 0.125 2.33 ± 0.46
TBARS in erythrocytes (nmol/gHb) 124.79 ± 46.41 132.09 ± 94.96 130.80 ± 68.86* 82.46 ± 34.16
AOPP (μmol/L) 40.15 ± 29.63 27.55 ± 17.59 32.63 ± 14.57 22.49 ± 20.24
SOD in plasma (U/ml) 3.61 ± 0.77 4.12 ± 0.46** 3.71 ± 0.48* 2.92 ± 0.96
SOD in erythrocytes (U/gHb) 10.37 ± 7.44 9.017 ± 2.09 9.02 ± 7.44 12.95 ± 7.54
Catalase in erythrocytes (U/ml/mgHb) 62.66 ± 44.04 75.71 ± 15.66 65.86 ± 23.98 80.13 ± 36.76
Values are shown as mean ± SD or median ± IQR
MEFV/R202Qhomo MEFV mutation carrier plus R202Q homozygotes group, Control N/N and R202Q/N, TBARS thiobarbituric acid reactive substances, AOPP
advanced oxidation protein products, SOD superoxide dismutase
*p < 0.05; **p < 0.001
Table 2 The absolute and relative frequencies of most common clinical manifestations in study subjects according to MEFV genotype
group
Clinical manifestations MEFV mutation carriers (n = 11) R202Q homozygotes (n = 10) MEFV/R202Qhomo (n = 20) Control (n = 76)
Reccurent febrile episodes 8 (72.7 %)* 8 (80 %)* 16 (80 %)** 31 (40.8 %)
Peritonitis 5 (45.5 %)** 3 (30 %) 8 (40 %)** 8 (10.5 %)
Fatigue/malaise 6 (54.5 %)** 4 (40 %) 10 (50 %)** 11 (14.5 %)
Diffuse abdominal pain 7 (63.6 %)* 6 (60 %)* 12 (60 %)** 21 (27.6 %)
Lymphadenopathy 3 (27.3 %) 7 (70 %)* 10 (50 %) 28 (36.8 %)
Oligoarthralgia 5 (45.5 %) 3 (30 %) 8 (40 %) 20 (26.3 %)
Myalgia 3 (27.3 %) 3 (30 %) 6 (30 %) 13 (17.1 %)
Values are shown as n (%)
MEFV/R202Qhomo MEFV mutation carrier plus R202Q homozygotes group, Control N/N and R202Q/N. Data for 4 subjects in control group were missing
*p < 0.05; **p ≤ 0.01 compared to control group
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responsible for autoinflammatory disease [4, 16, 17].
Recognition of an inflammatory phenotype in single-
mutation cases suggests that mutations lead to a gain-
of-function with gene-dosage effect, rather than a simple
loss-of-function recessive model, which has been consid-
ered their primary result [2, 18–20].
We observed a very high R202Q heterozygous carrier
rate (45 %), as well as R202Q homozygosity in healthy
individuals (10 %) compared to other studies, but with-
out any clear influence on the phenotype. On the con-
trary, R202Q homozygosity was found in 9.2 % of Greek
FMF patients [20] and in 43 % of Turkish FMF patients
[22] in whom the phenotype corresponded to the charac-
teristic autoinflammatory phenotype, with fever, serositis
and monoarthritis occurring most frequently. Karakus et
al. [37] showed that homozygous R202Q genotype was
significantly higher in fibromyalgia patients than in
healthy controls, and that morning fatique and irritable
bowel syndrome had significant associations with this
polymorphism.
In addition to the inflammatory symptoms, increased
oxidative stress has been reported in AID patients dur-
ing attacks, as well as in remission periods [14, 15]. It
has been reported that neutrophils harboring MEFV
gene mutations produce high levels of superoxide anion
without any stimulation [6].
Since erythrocytes effectively scavenge reactive oxygen
species, their membranes are simultaneously influenced
by free radicals, intracellular antioxidative systems and
plasma antioxidants. They are therefore regarded as a
good indicator of lipid peroxidation [38]. The subjects in
MEFV/R202Qhomo group in this study had significantly
higher concentrations of erythrocytes TBARS, which
might partly be the result of insufficient or depleted cel-
lular antioxidant protection. The erythrocyte SOD and
catalase activity were decreased in these persons but not
statisticaly significant, and this should be reanalysed in a
larger study group. It has been reported that FMF
patients have significantly decreased activities of these
enzymes in the attack period [13, 14]. Advanced oxida-
tion protein products are novel oxidative stress and
inflammation markers. Activated neutrophils are shown
to participate directly in their formation [39]. There are
no many studies evaluating the AOPP levels in FMF
patients with MEFV mutations. Sahin et al. [40] deter-
mined lower AOPP levels in FMF patients with attack-
Fig. 2 The clinical manifestations between mutation carriers with R202Q homozygotes and persons without MEFV gene changes. *p < 0.026.
MEFV/R202Qhomo - MEFV mutation carrier plus R202Q homozygotes group, Control group - N/N and R202Q/N
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free period than in controls. They studied AOPP levels
according to the paraoxonase phenotype and found that
FMF patients with a QQ phenotype exhibited lower
AOPP levels than the controls, while there was not sig-
nificant difference if the patients had QR + RR paraoxo-
nase phenotype. However, comparably, free thiol levels
and protein carbonyl groups are changed in the attack
periods, decreased and increased respectively [13, 14].
Although not statistically significant, AOPP levels were
increased in MEFV/R202Qhomo group subjects and
positively correlated with TBARS erythrocyte levels. This
all implies on a complex oxidative regulation depending
on various factors.
The major SOD isoenzyme in plasma is CuZn-
extracellular SOD (EC-SOD), mostly secreted by endo-
thelial cells [41, 42]. Leukocytes produce high levels of
superoxide anion after activation and EC-SOD is the
main enzymatic scavenger in the extracellular matrix.
Compared to other antioxidative enzymes, induction
and regulation of EC-SOD is governed by cytokines
and not its substrate O2
− or other oxidants [43, 44]. El-
evated plasma SOD levels were reported to reflect a
response to increased oxidative stress in cancer pa-
tients and were implicated as a sensitive marker of in-
flammatory processes [45, 46]. Moreover, increased
plasma SOD activity was observed in severe forms of
acute appendicitis, indicating increased neutrophil in-
filtration and inflammation [47]. Considering inflam-
masome dysfunction in leukocytes with mutated pyrin,
the increased plasma SOD activity in our study was
perhaps an adaptive response to enhanced leukocyte
activation and IL-1β release, since the leukocyte count
was not significantly changed.
Most prevalent clinical manifestations in a FMF attack
are fever and abdominal pain due to peritonitis [2, 3].
These symptoms are seen not only in homozygotes for
the most common MEFV mutations, but also in com-
pound heterozygote carriers [20, 34]. Healthy volunteers
in our study could not be diagnosed as FMF or any other
AID, but the mutation carriers and R202Q homozygotes
reported recurrent fever and diffuse abdominal pain
significantly more often than non-carriers. This could in-
dicate that persons with heterozygous mutations and
R202Q/R202Q changes had an impaired innate immunity
response. Additionally, this might imply an increased risk
of developing inflammatory conditions during life. Unfor-
tunately, due to the cross-sectional design of our study,
this can be only speculated about, and prospective (life
time) clinical follow-up studies are therefore warranted.
However, neither mutation nor R202Q/R202Q could
predict an inflammatory outcome in our study. The per-
sons affected had occasional health problems that could
not be significantly associated with the presence of de-
tected gene changes. Additionally, there were no signs of
subclinical inflammation. Types and frequency of clinical
manifestations in R202Q homozygotes group were not
different in comparison to the E148Q and K695R hetero-
zygotes, pointing to the similar effect of this MEFV gene
change. An influence of gene-dosage effect could be pro-
posed, as R202Q heterozygosity was quite frequent but
was not associated with a particular health problem.
Although R202Q homozygosity was found in patients
with typical FMF presentation in other studies [21, 22] the
symptoms reported by our R202Q homozygotes were
mild, atypical and often without accompanying fever. This
is perhaps the consequence of an incomplete penetrance
or variable expressivity of R202Q in the Serbian popula-
tion caused by the influence of additional genetic or envir-
onmental factors characteristic for this region.
Conclusion
Healthy individuals may bear E148Q or K695R muta-
tions of the MEFV gene, as well as R202Q alteration in
the homozygous state in Serbia. An incomplete pene-
trance or variable expressivity of R202Q in populations
of different ethnicity could influence the expression of
autoinflammatory disease phenotypes. These gene
changes may influence innate immunity and oxidative
stress regulation. MEFV gene changes do not necessarily
induce an autoinflammatory disease in the Serbian
population, but may be responsible for more frequent
occurrence of fever episodes and unspecific inflamma-
tory manifestations in carriers.
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